cccDNA
环状DNA
乙型肝炎病毒
乙型肝炎表面抗原
医学
微小染色体
病毒学
DNA
癌症研究
生物
病毒
基因
遗传学
基因组
染色质
作者
María del Carmen Jiménez Martínez,Anders Boyd,Emmanuel Combe,Barbara Testoni,Fabien Zoulim
标识
DOI:10.1016/j.jhep.2021.05.013
摘要
Current antiviral therapies, such as pegylated interferon-α and nucleos(t)ide analogues, effectively improve the quality of life of patients with chronic hepatitis B. However, they can only control the infection rather than curing infected hepatocytes. Complete HBV cure is hampered by the lack of therapies that can directly affect the viral minichromosome (in the form of covalently closed circular DNA [cccDNA]). Approaches currently under investigation in early clinical trials are aimed at achieving a functional cure, defined as the loss of HBsAg and undetectable HBV DNA levels in serum. However, achieving a complete HBV cure requires therapies that can directly target the cccDNA pool, either via degradation, lethal mutations or functional silencing. In this review, we discuss cutting-edge technologies that could lead to non-cytolytic direct cccDNA targeting and cure of infected hepatocytes.
科研通智能强力驱动
Strongly Powered by AbleSci AI